The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pharmaceutical Contract Research Services Market by Scale of Operation (Discovery, Preclinical and Clinical Stage), Target Therapeutic Areas (Cardiovascular, Dermatological, Infectious, Inflammatory, Neurological, Oncological, Ophthalmological, Respiratory and Other) and Key Geographies (North America, Europe, Asia- Pacific, Latin America, MENA (Middle East and North Africa) and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2021

  • Pages
    503

  • View Count
    487

Example Insights

Pharmaceutical-Contract-Research-Services-Market-Context Pharmaceutical-Contract-Research-Services-Market-List-of-service-providers Pharmaceutical-Contract-Research-Services-Market-Different-scales-of-operation Pharmaceutical-Contract-Research-Services-Market-Distribution-by-Location-of-Headquarters
Pharmaceutical-Contract-Research-Services-Market-Competitiveness-Analysis Pharmaceutical-Contract-Research-Services-Market-Partnerships-and-Collaborations Pharmaceutical-Contract-Research-Services-Market-Mergers-and-Acquisitions Pharmaceutical-Contract-Research-Services-Market-Case-Study
Pharmaceutical-Contract-Research-Services-Market-Distribution-by-Geographical-Region Pharmaceutical-Contract-Research-Services-Market-Opportunity    

 

Overview

Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In 2020, the US FDA’s Center for Drug Evaluation and Research approved 35 small molecule drugs, representing 66% of the total number of new molecular entities (NMEs) clearing regulatory review in the same year.  It is worth highlighting that the process of drug development, beginning from the discovery of a pharmacological lead to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase, actually make it into the clinical phase, and an even lesser number of product candidates enter the market. Therefore, to optimize on internal resource utilization and save costs, innovator companies in the pharmaceutical industry are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs). 

Modern CROs offer a plethora of pharmaceutical discovery (such as target discovery & validation, hit identification (using strategies such as high-throughput screening, fragment-based screening, virtual screening, knowledge-based screening and DNA-encoded libraries), and lead generation / optimization) and product development related services, leveraging a variety of advanced technologies to cater to the evolving needs of sponsors / clients. As indicated earlier, engaging third party service providers offers both time and cost related benefits to drug / therapy developers. Currently, over 500 companies / organization claim to be actively providing contract research services for small molecule drugs. In the recent past, many of the service providers in this domain forged strategic alliances and / or acquired other players, in order to further enhance their respective service portfolios and thereby, consolidate their presence in the industry. The aforementioned developments may be attributed to the growing preference for one-stop-shops among sponsor companies, and the gradual acceptance of outsourcing as a viable and beneficial operating model. Based on prevalent trends and projections of how the pharmaceutical pipeline is likely to evolve over the coming years, we believe that demand for pharmaceutical CROs is going to grow at a steady pace. Consequently, the small molecule drug discovery and development services market is anticipated to witness consistent growth till 2030.

Scope of the Report

The "Pharmaceutical Contract Research Services Market, 2021-2030" report features an extensive study on contract service providers engaged in discovery, preclinical and clinical research of small molecule drugs. The study features in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the pharmaceutical services market, highlighting the contributions of CROs, along with information on their year of establishment, company size, scale of operation (discovery, preclinical and clinical), location of headquarters, type(s) of services offered (target discovery & validation, hit identification, hit-to-lead & lead generation, lead optimization, bioanalytical studies, other preclinical services, clinical trials related services, consulting and regulatory affairs management), hit identification strategy used (high-throughput screening, fragment based screening, virtual screening (structure based virtual screening, ligand based virtual screening and unspecified virtual screening), knowledge based screening, DNA Encoded Library (DEL) based screening and others), type of business model (fee-for-service and full time equivalent) and target therapeutic area. 
  • Elaborate profiles of prominent CROs engaged in offering pharmaceutical related services. Each company profile features a brief overview of the company, its financial information (if available), service portfolio and recent developments and an informed future outlook.
  • An insightful competitiveness analysis, highlighting prominent pharmaceutical contract service providers based on supplier strength (considering a company's years of experience), and service strength (which takes into account the service offerings, scale of operation, hit identification strategies and subject specific agreements).
  • An analysis of the recent collaborations (signed since 2018) focused on the CROs offering pharmaceutical related services, based on various parameters, such as year of agreement, type of agreement, scale of operation and target therapeutic area.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2018-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition and geographical location of the companies.
  • A region-wise, detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider. It features an informed estimate of direct and indirect expenses taking into consideration close to 100 relevant parameters over a span of 20 years.
  • A case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical CROs market over the coming decade. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] scale of operation (discovery services, preclinical services and clinical stage services), [B] target therapeutic area (cardiovascular disorder, dermatological disorders, infectious disorder, inflammatory disorder, neurological disorder, oncological disorder,  ophthalmological disorder, respiratory disorder and other disorders) and [C] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).  In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Scope of the Report

  • Who are the leading players offering contract research services for small molecules?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What are the key value drivers of the merger and acquisition activity observed within this domain?
  • What are the likely future trends in contract research services market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What is the total cost of ownership required to set up a pharmaceutical contract research organization?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the pharmaceutical CROs market in the mid to long term. 

Chapter 3 provides a general introduction to the process of drug discovery and development. The chapter highlights the challenges associated with small molecule drug discovery along with a detailed discussion on the need for outsourcing within the pharmaceutical industry and guidelines for selecting the right service provider.

Chapter 4 provides a comprehensive overview of the global pharmaceutical services market, highlighting the contributions of over 500 CROs. It features a detailed assessment of the market, based on a number of relevant parameters, such as year of establishment, company size, scale of operation (discovery, preclinical and clinical), location of headquarters, types of services offered (target discovery & validation, hit identification, hit-to-lead and lead generation, lead optimization, bioanalytical studies, other preclinical services, clinical trials related services, consulting and regulatory affairs management), hit identification strategy used (high-throughput screening, fragment based screening, virtual screening (structure based virtual screening, ligand based virtual screening and unspecified virtual screening), knowledge based screening, DNA Encoded Library (DEL) based screening and others), type of business model (fee-for-service and full time equivalent) and target therapeutic area.

Chapter 5 provides detailed profiles of some of the key players that are active in the pharmaceutical contract research services market. Each profile presents a brief overview of the company, its financial information (if available), service portfolio and recent developments and an informed future outlook. 

Chapter 6 features a comprehensive company competitiveness analysis, highlighting prominent pharmaceutical contract service providers based in North America, Europe, Asia-Pacific and Rest of the world, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (considering a company’s years of experience), and service strength (which takes into account the service offerings, scale of operation, hit identification strategies and subject specific agreements).

Chapter 7 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2018. It includes brief descriptions of the various partnership models (including acquisition, clinical trial, platform utilization, product development, research, research and development, service, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation and target therapeutic area. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 presents a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2018-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition and geographical location of the companies.

Chapter 9 presents an insightful market forecast analysis, highlighting the likely growth of the pharmaceutical CROs market till the year 2031. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] scale of operation (discovery services, preclinical services and clinical stage services), [B] target therapeutic area (cardiovascular disorder, dermatological disorder, infectious disorder, inflammatory disorder, neurological disorder, oncological disorder,  ophthalmological disorder, respiratory disorder and other disorders) and [C] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).  

Chapter 10 features a detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider in key geographical regions (US, Europe and Asia-Pacific). It presents estimated direct and indirect expenses taking into consideration close to 100 relevant parameters over a span of 20 years.

Chapter 11 features a case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered.

Chapter 12 features the transcript of the discussion(s) held with key stakeholder(s) in the industry. 

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Discovery and Validation
3.3.3. Hit Generation 
3.3.3.1. High-Throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA-Encoded Libraries Screening
3.3.4. Hit-to-Lead and Lead Generation
3.3.5. Lead Optimization

3.4. Challenges Associated with Small Molecule Discovery
3.5. Need for Outsourcing Drug Discovery Operations
3.6 Guidelines for Selecting a Contract Research Service Provider
3.7. Concluding Remarks

4. PHARMACEUTICAL CONTRACT RESEARCH SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical Contract Research Service Providers: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Company Size and Scale of Operation 
4.2.6. Analysis by Types of Services Offered
4.2.7. Analysis by Location of Headquarters and Types of Services Offered 
4.2.8. Analysis by Hit Identification Strategy Used 
4.2.9. Analysis by Type of Business Model
4.2.10. Analysis by Target Therapeutic Area

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Pharmaceutical Contract Research Service Providers in North America
5.2.1. Albany Molecular Research (AMRI)
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Service Portfolio
5.2.1.4. Recent Developments and Future Outlook

5.2.2. BioDuro
5.2.2.1. Company Overview
5.2.2.2. Service Portfolio
5.2.2.3. Recent Developments and Future Outlook

5.2.3. BOC Sciences
5.2.3.1. Company Overview
5.2.3.2. Service Portfolio
5.2.3.3. Recent Developments and Future Outlook

5.2.4. Catalent Pharma
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Service Portfolio
5.2.4.4. Recent Developments and Future Outlook

5.2.5. Charles River Laboratories
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Service Portfolio
5.2.5.4. Recent Developments and Future Outlook

5.2.6. ChemDiv
5.2.6.1. Company Overview
5.2.6.2. Service Portfolio
5.2.6.3. Recent Developments and Future Outlook

5.2.7. Covance
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Service Portfolio
5.2.7.4. Recent Developments and Future Outlook

5.2.8. Medpace
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Service Portfolio
5.2.8.4. Recent Developments and Future Outlook

5.2.9. QPS
5.2.9.1. Company Overview
5.2.9.2. Service Portfolio
5.2.9.3. Recent Developments and Future Outlook

5.3. Pharmaceutical Contract Research Service Providers in Europe
5.3.1. Concept Life Sciences
5.3.1.1. Company Overview
5.3.1.2. Service Portfolio
5.3.1.3. Recent Developments and Future Outlook

5.3.2. Evotec
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Service Portfolio
5.3.2.4. Recent Developments and Future Outlook

5.4. Pharmaceutical Contract Research Service Providers in Asia-Pacific
5.4.1. ChemPartner
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Service Portfolio
5.4.1.4. Recent Developments and Future Outlook

5.4.2. Pharmaron
5.4.2.1. Company Overview
5.4.2.2. Service Portfolio
5.4.2.3. Recent Developments and Future Outlook

5.4.3. Syngene
5.4.3.1. Company Overview
5.4.3.2. Financial Information
5.4.3.3. Service Portfolio
5.4.3.4. Recent Developments and Future Outlook

5.4.4. Torrent Pharma
5.4.4.1. Company Overview
5.4.4.2. Financial Information
5.4.4.3. Service Portfolio
5.4.4.4. Recent Developments and Future Outlook

5.4.5. WuXi AppTec
5.4.5.1. Company Overview
5.4.5.2. Financial Information
5.4.5.3. Service Portfolio
5.4.5.4. Recent Developments and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers
6.4.1. Pharmaceutical Contract Research Service Providers based in North America
6.4.2. Pharmaceutical Contract Research Service Providers based in Europe
6.4.3. Pharmaceutical Contract Research Service Providers based in Asia- Pacific and Rest of the World

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Target Therapeutic Area
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Regional Analysis 
7.3.8.1. Intercontinental and Intracontinental Agreements

8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Merger and Acquisition Models
8.3. Pharmaceutical Contract Research Service Providers: Mergers and Acquisitions
8.3.1. Analysis by Year of Acquisition
8.3.2. Analysis by Geography
8.3.3. Intercontinental and Intracontinental Deals
8.4. Analysis by Key Value Drivers
8.4.1. Mergers and Acquisitions: Analysis by Key Value Drivers
8.5. Valuation Analysis: Acquisition Deal Multiples
8.5.1. Prominent Acquirers: Analysis by Number of Acquisitions

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030
9.4. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030: Distribution by Scale of Operation
9.4.1. Global Pharmaceutical Contract Research Service Providers Market for Discovery Services, 2021-2030
9.4.2. Global Pharmaceutical Contract Research Service Providers Market for Preclinical Services, 2021-2030
9.4.3. Global Pharmaceutical Contract Research Service Providers Market for Clinical Services, 2021-2030

9.5. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030: Distribution by Target Therapeutic Area
9.5.1. Global Pharmaceutical Contract Research Service Providers Market for Oncological Disorders, 2021-2030
9.5.2. Global Pharmaceutical Contract Research Service Providers Market for Infectious Diseases, 2021-2030
9.5.3. Global Pharmaceutical Contract Research Service Providers Market for Neurological Disorders, 2021-2030
9.5.4. Global Pharmaceutical Contract Research Service Providers Market for Inflammatory Disorders, 2021-2030
9.5.5. Global Pharmaceutical Contract Research Service Providers Market for Cardiovascular Disorders, 2021-2030
9.5.6. Global Pharmaceutical Contract Research Service Providers Market for Dermatological Disorders, 2021-2030
9.5.7. Global Pharmaceutical Contract Research Service Providers Market for Ophthalmological Diseases, 2021-2030
9.5.8. Global Pharmaceutical Contract Research Service Providers Market for Respiratory Disorders, 2021-2030
9.5.9. Global Pharmaceutical Contract Research Service Providers Market for Other Disorders, 2021-2030

9.6. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030: Distribution by Region
9.6.1. Pharmaceutical Contract Research Service Providers Market in North America, 2021-2030
9.6.2. Pharmaceutical Contract Research Service Providers Market in Europe, 2021-2030
9.6.3. Pharmaceutical Contract Research Service Providers Market in Asia-Pacific, 2021-2030
9.6.4. Pharmaceutical Contract Research Service Providers Market in Middle East, 2021-2030
9.6.5. Pharmaceutical Contract Research Service Providers Market in Latin America, 2021-2030

10. TOTAL COST OF OWNERSHIP IN PHARMACEUTICAL CONTRACT RESEARCH ORGANIZATION
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Output

11. CASE STUDY: BIOPHARMACEUTICAL CONTRACT RESEARCH SERVICES MARKET
11.1. Chapter Overview
11.2. Biopharmaceutical CROs: Overall Market Landscape
11.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
11.2.2. Analysis by Scale of Operation

11.3. Preclinical Biopharmaceutical CROs
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Location of Headquarters
11.3.4. Analysis by Type of Biologic
11.3.5. Analysis by Type of Services Offered

11.4. Clinical Biopharmaceutical CROs
11.4.1. Analysis by Year of Establishment
11.4.2. Analysis by Company Size
11.4.3. Analysis by Location of Headquarters
11.4.4. Analysis by Type of Biologics
11.4.5. Analysis by Type of Services Offered

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. ChemoGenics Biopharma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Francis X. Tavares, Founder and Chief Executive Officer

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

List Of Figures

Figure 3.1 Drug Discovery and Development Pipeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Guidelines for Selecting a Contract Research Service Provider
Figure 4.1 Pharmaceutical Contract Research Service Providers: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical Contract Research Service Providers: Distribution by Company Size
Figure 4.3 Pharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Figure 4.4 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters
Figure 4.5 World Map Representation: Analysis by Geography
Figure 4.6 Pharmaceutical Contract Research Service Providers: Distribution by Company Size and Scale of Operation
Figure 4.7 Pharmaceutical Contract Research Service Providers: Distribution by Types of Services Offered
Figure 4.8 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters and Types of Services Offered
Figure 4.9 Pharmaceutical Contract Research Service Providers: Distribution by Hit Identification Strategy Used
Figure 4.10 Pharmaceutical Contract Research Service Providers: Distribution by Type of Business Model
Figure 4.11 Pharmaceutical Contract Research Service Providers: Distribution by Target Therapeutic Area
Figure 5.1 Catalent Pharma: Annual Revenues, 2016-9M 2021 (USD Billion)
Figure 5.2 Charles River Laboratories: Annual Revenues, 2016-3M 2021 (USD Billion)
Figure 5.3 Covance: Annual Revenues, 2016-3M 2021 (USD Billion)
Figure 5.4 Medpace: Annual Revenues, 2016-3M 2021 (USD Billion)
Figure 5.5 Evotec: Annual Revenues, 2016-3M 2021 (EUR Million)
Figure 5.6 Syngene: Annual Revenues, 2016-2021 (INR Billion)
Figure 5.7 Torrent Pharma: Annual Revenues, 2016-2021 (INR Million)
Figure 5.8 WuXi AppTec: Annual Revenues, 2017-3M 2021 (RMB Billion)
Figure 6.1 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in Asia Pacific and Rest of the World
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 7.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 7.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.8 Most Active Players: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Regional Distribution
Figure 7.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (2018- 2021)
Figure 8.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 8.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 8.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 8.5 Mergers and Acquisitions: Region-wise Distribution
Figure 8.6 Mergers and Acquisitions: Country-wise Distribution
Figure 8.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 8.8 Mergers and Acquisitions: Key Value Drivers
Figure 8.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 8.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 8.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Figure 9.1 Global Pharmaceutical Contract Research Services Market, 2021-2030 (USD Billion)
Figure 9.2 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 9.3 Global Pharmaceutical Contract Research Services Market for Discovery Services, 2021-2030 (USD Billion)
Figure 9.4 Global Pharmaceutical Contract Research Services Market for Preclinical Services, 2021-2030 (USD Billion)
Figure 9.5 Global Pharmaceutical Contract Research Services Market for Clinical Stage Services, 2021-2030 (USD Billion)
Figure 9.6 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Target Therapeutic Area (USD Billion)
Figure 9.7 Global Pharmaceutical Contract Research Services Market for Oncological Disorders, 2021-2030 (USD Billion)
Figure 9.8 Global Pharmaceutical Contract Research Services Market for Infectious Diseases, 2021-2030 (USD Billion)
Figure 9.9 Global Pharmaceutical Contract Research Services Market for Neurological Disorders, 2021-2030 (USD Billion)
Figure 9.10 Global Pharmaceutical Contract Research Services Market for Inflammatory Disorders, 2021-2030 (USD Billion)
Figure 9.11 Global Pharmaceutical Contract Research Services Market for Cardiovascular Disorders, 2021-2030 (USD Billion)
Figure 9.12 Global Pharmaceutical Contract Research Services Market for Dermatological Disorders, 2021-2030 (USD Billion)
Figure 9.13 Global Pharmaceutical Contract Research Services Market for Ophthalmological Diseases, 2021-2030 (USD Billion)
Figure 9.14 Global Pharmaceutical Contract Research Services Market for Respiratory Disorders, 2021-2030 (USD Billion)
Figure 9.15 Global Pharmaceutical Contract Research Services Market for Other Disorders, 2021-2030 (USD Billion)
Figure 9.16 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Geography (USD Billion)
Figure 9.17 Global Pharmaceutical Contract Research Services Market in North America, 2021-2030 (USD Billion)
Figure 9.18 Global Pharmaceutical Contract Research Services Market in Europe, 2021-2030 (USD Billion)
Figure 9.19 Global Pharmaceutical Contract Research Services Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 9.20 Global Pharmaceutical Contract Research Services Market in Middle East and North Africa, 2021-2030 (USD Billion)
Figure 9.21 Global Pharmaceutical Contract Research Services Market in Latin America, 2021-2030 (USD Billion)
Figure 10.1 Total Cost of Ownership in Pharmaceutical Contract Research Organization: Output
Figure 11.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 11.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Figure 11.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Figure 11.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Figure 11.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Figure 11.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Figure 11.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Figure 11.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Figure 11.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 11.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Figure 11.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
Figure 11.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Figure 11.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Figure 11.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Figure 11.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Figure 11.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Partnerships and Collaborations
Figure 13.3 Concluding Remarks: Mergers and Acquisitions
Figure 13.4 Concluding Remarks: Market Forecast
Figure 13.5 Concluding Remarks: Total Cost of Ownership in Pharmaceutical Contract Research Organization

List Of Tables

Table 4.1 Pharmaceutical Contract Research Service Providers: List of Industry Players
Table 4.2 Pharmaceutical Contract Research Service Providers: Information on Scale of Operation
Table 4.3 Pharmaceutical Contract Research Service Providers: Information on Types of Services Offered
Table 4.4 Pharmaceutical Contract Research Service Providers: Information on Hit Identification Strategy Used
Table 4.5 Pharmaceutical Contract Research Service Providers: Information on Type of Business Model
Table 4.6 Pharmaceutical Contract Research Service Providers: Information on Type of Business Model
Table 4.7 Pharmaceutical Contract Research Service Providers: Information on Target Therapeutic Area
Table 5.1 Pharmaceutical Contract Research Service Providers: List of Profiled Companies
Table 5.2 AMRI: Company Overview
Table 5.3 AMRI: Service Portfolio
Table 5.4 AMRI: Recent Developments and Future Outlook
Table 5.5 BioDuro: Company Overview
Table 5.6 BioDuro: Service Portfolio
Table 5.7 BioDuro: Recent Developments and Future Outlook
Table 5.8 BOC Sciences: Company Overview
Table 5.9 BOC Sciences: Service Portfolio
Table 5.10 BOC Sciences: Recent Developments and Future Outlook
Table 5.11 Catalent Pharma: Company Overview
Table 5.12 Catalent Pharma: Service Portfolio
Table 5.13 Catalent Pharma: Recent Developments and Future Outlook
Table 5.14 Charles River Laboratories: Company Overview
Table 5.15 Charles River Laboratories: Service Portfolio
Table 5.16 Charles River Laboratories: Recent Developments and Future Outlook
Table 5.17 ChemDiv: Company Overview
Table 5.18 ChemDiv: Service Portfolio
Table 5.19 ChemDiv: Recent Developments and Future Outlook
Table 5.20 Covance: Company Overview
Table 5.21 Covance: Service Portfolio
Table 5.22 Covance: Recent Developments and Future Outlook
Table 5.23 Medpace: Company Overview
Table 5.24 Medpace: Service Portfolio
Table 5.25 Medpace: Recent Developments and Future Outlook
Table 5.26 QPS: Company Overview
Table 5.27 QPS: Service Portfolio
Table 5.28 QPS: Recent Developments and Future Outlook
Table 5.29 Concept Life Sciences: Company Overview
Table 5.30 Concept Life Sciences: Service Portfolio
Table 5.31 Concept Life Sciences: Recent Developments and Future Outlook
Table 5.32 Evotec: Company Overview
Table 5.33 Evotec: Service Portfolio
Table 5.34 Evotec: Recent Developments and Future Outlook
Table 5.35 ChemPartner: Company Overview
Table 5.36 ChemPartner: Service Portfolio
Table 5.37 ChemPartner: Recent Developments and Future Outlook
Table 5.38 Pharmaron: Company Overview
Table 5.39 Pharmaron: Service Portfolio
Table 5.40 Pharmaron: Recent Developments and Future Outlook
Table 5.41 Syngene: Company Overview
Table 5.42 Syngene: Service Portfolio
Table 5.43 Syngene: Recent Developments and Future Outlook
Table 5.44 Torrent Pharma: Company Overview
Table 5.45 Torrent Pharma: Service Portfolio
Table 5.46 Torrent Pharma: Recent Developments and Future Outlook
Table 5.47 WuXi AppTec: Company Overview
Table 5.48 WuXi AppTec: Service Portfolio
Table 5.49 WuXi AppTec: Recent Developments and Future Outlook
Table 7.1 Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
Table 8.1 Mergers and Acquisitions: List of Mergers / Acquisitions, 2018-2021
Table 8.2 Mergers and Acquisitions: Information on Key Value Drivers, 2018-2021
Table 8.3 Mergers and Acquisitions: Deal Multiples, 2018-2021
Table 11.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
Table 11.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
Table 12.1 ChemoGenics Biopharma: Key Highlights
Table 14.1 Pharmaceutical Contract Research Service Providers: Distribution by Year of Establishment
Table 14.2 Pharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Table 14.3 Pharmaceutical Contract Research Service Providers: Distribution by Company Size
Table 14.4 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters
Table 14.5 World Map Representation: Analysis by Geography
Table 14.6 Pharmaceutical Contract Research Service Providers: Distribution by Company Size and Scale of Operation
Table 14.7 Pharmaceutical Contract Research Service Providers: Distribution by Types of Services Offered
Table 14.9 Pharmaceutical Contract Research Service Providers: Distribution by Hit Identification Strategy Used
Table 14.10 Pharmaceutical Contract Research Service Providers: Distribution by Type of Business Model
Table 14.11 Pharmaceutical Contract Research Service Providers: Distribution by Target Therapeutic Area
Table 14.12 Catalent Pharma: Annual Revenues, 2016-9M 2021 (USD Billion)
Table 14.13 Charles River Laboratories: Annual Revenues, 2016-3M 2021 (USD Billion)
Table 14.14 Covance: Annual Revenues, 2016-3M 2021 (USD Billion)
Table 14.15 Medpace: Annual Revenues, 2016-3M 2021 (USD Billion)
Table 14.16 Evotec: Annual Revenues, 2016-3M 2021 (EUR Million)
Table 14.17 Syngene: Annual Revenues, 2016-2021 (INR Billion)
Table 14.18 Torrent Pharma: Annual Revenues, 2016-2021 (INR Million)
Table 14.19 WuXi AppTec: Annual Revenues, 2017-3M 2021 (RMB Billion)
Table 14.20 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
Table 14.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.22 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.23 Partnerships and Collaborations: Distribution by Scale of Operation
Table 14.24 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 14.25 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.27 Most Active Players: Distribution by Number of Partnerships
Table 14.28 Partnerships and Collaborations: Regional Distribution
Table 14.29 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.30 Mergers and Acquisitions: List of Mergers / Acquisitions, 2016 - 2020
Table 14.31 Mergers and Acquisitions: Information on Key Value Drivers, 2016- 2020
Table 14.32 Mergers and Acquisitions: Deal Multiples, 2016- 2020
Table 14.33 Global Pharmaceutical Contract Research Services Market, 2021-2030 (USD Billion)
Table 14.34 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 14.35 Global Pharmaceutical Contract Research Services Market for Discovery Services, 2021-2030 (USD Billion)
Table 14.36 Global Pharmaceutical Contract Research Services Market for Preclinical Services, 2021-2030 (USD Billion)
Table 14.37 Global Pharmaceutical Contract Research Services Market for Clinical Stage Services, 2021-2030 (USD Billion)
Table 14.38 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Target Therapeutic Area (USD Billion)
Table 14.39 Global Pharmaceutical Contract Research Services Market for Oncological Disorders, 2021-2030 (USD Billion)
Table 14.40 Global Pharmaceutical Contract Research Services Market for Infectious Diseases, 2021-2030 (USD Billion)
Table 14.41 Global Pharmaceutical Contract Research Services Market for Neurological Disorders, 2021-2030 (USD Billion)
Table 14.42 Global Pharmaceutical Contract Research Services Market for Inflammatory Disorders, 2021-2030 (USD Billion)
Table 14.43 Global Pharmaceutical Contract Research Services Market for Cardiovascular Disorders, 2021-2030 (USD Billion)
Table 14.44 Global Pharmaceutical Contract Research Services Market for Dermatological Disorders, 2021-2030 (USD Billion)
Table 14.45 Global Pharmaceutical Contract Research Services Market for Ophthalmological Disorders, 2021-2030 (USD Billion)
Table 14.46 Global Pharmaceutical Contract Research Services Market for Respiratory Disorders, 2021-2030 (USD Billion)
Table 14.47 Global Pharmaceutical Contract Research Services Market for Other Disorders, 2021-2030 (USD Billion)
Table 14.48 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Geography (USD Billion)
Table 14.49 Global Pharmaceutical Contract Research Services Market in North America, 2021-2030 (USD Billion)
Table 14.50 Global Pharmaceutical Contract Research Services Market in Europe, 2021-2030 (USD Billion)
Table 14.51 Global Pharmaceutical Contract Research Services Market in Asia-Pacific, 2021-2030 (USD Billion)
Table 14.52 Global Pharmaceutical Contract Research Services Market in Middle East and North Africa, 2021-2030 (USD Billion)
Table 14.53 Global Pharmaceutical Contract Research Services Market in Latin America, 2021-2030 (USD Billion)
Table 14.54 Total Cost of Ownership in Pharmaceutical Contract Research Organization: Output
Table 14.55 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 14.56 Biopharmaceutical CROs: Distribution by Scale of Operation
Table 14.57 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Table 14.58 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Table 14.59 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Table 14.60 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Table 14.61 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Table 14.62 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Table 14.63 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Table 14.64 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Table 14.65 Biopharmaceutical Clinical CROs: Distribution by Company Size
Table 14.66 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Table 14.67 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Table 14.68 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Table 14.69 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Table 14.70 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered

List Of Companies

  1. 2bind
  2. 4Clinics
  3. A+ Science
  4. A10 Clinical Solutions
  5. A2 Healthcare
  6. Aaranya Biosciences
  7. AbClon 
  8. Absolute Research Solutions
  9. Absorption Systems
  10. Accelera
  11. Accelero Biostructures
  12. Accell Clinical Research
  13. Accelsiors
  14. Accre Chemicals
  15. Accuprec Research Labs
  16. Accutest Research Laboratories
  17. ACD/Labs
  18. ACEA Biosciences
  19. ACI Clinical
  20. Aclaris Therapeutics
  21. ACLIRES International
  22. ACM Global Laboratories
  23. aCROnordic 
  24. ACROVAN
  25. Actimus Bio
  26. Activa Cro
  27. Addex Therapeutics
  28. Adesis
  29. Advanced Clinical
  30. Advanced Drug and Device Services (ADDS)
  31. Aepodia
  32. African Clinical Research Organization (ACRO) 
  33. Agilent
  34. AGINKO Research
  35. Agno Pharma
  36. AiPing Pharmaceutical
  37. AIT Bioscience
  38. Aix Scientifics
  39. Aizant Drug Research Solutions
  40. Akcelis
  41. Albuquerque Clinical Trials
  42. Alcami
  43. Alimentiv
  44. Alira Health
  45. Alliance Pharma
  46. Allphase Clinical Research
  47. Almac
  48. Almirall
  49. Alpha Bioresearch
  50. Alpha Genesis (AGI)
  51. Altasciences
  52. Althian- Clinical Research Management Center
  53. Altiora
  54. Alturas Analytics
  55. Amarex Clinical Research
  56. AmbioPharma
  57. Amedes
  58. American Preclinical Services
  59. AML Clinical Services
  60. AMRI
  61. Anabase International
  62. Analgesic Solutions
  63. Anapharm Bioanalytics
  64. Anavo Therapeutics
  65. ANI Pharmaceuticals
  66. Anova Enterprises
  67. AnSys Laboratories
  68. ANTAEA
  69. Antev
  70. APCER Life Sciences
  71. APEIRON Biologics
  72. A-Pharma
  73. Appletree CI Group
  74. Applied Healthcare Resource Management (AHRM)
  75. APRO
  76. ARCHIMEDlife
  77. Arcinova
  78. Argint International Clinical Research and Development Services (Argint)
  79. Aris Pharmaceuticals
  80. Array Biostatistics (Acquired by CATO SMS)
  81. Asclepia Medchem Solutions
  82. Asia Global Research (AGR)
  83. Asiatic Clinical Research
  84. ASINEX
  85. ASSAY Clinical Research
  86. Assay.Works
  87. Astron Research
  88. AstronauTx
  89. Atlant Clinical
  90. Atuka
  91. August Bioservices
  92. Auriga Research
  93. Aurigene Pharmaceutical Services
  94. Aurora Fine Chemicals
  95. Aurum Clinical Research (ACR)
  96. Avance Clinical (formerly CPR Pharma Services)
  97. Averica Discovery 
  98. Avistron Chemistry Services
  99. Avitacor
  100. AVVA Pharmaceuticals
  101. AXIS Clinicals
  102. Axon Clinical Research
  103. Axon Medchem
  104. Axxam
  105. Azidus
  106. BalticCRO
  107. Biomedical Advanced Research and Development Authority (BARDA)
  108. BASF
  109. Baxter
  110. Bayer
  111. BBK Worldwide
  112. BePharBel Manufacturing
  113. Bienta (a part of Enamine Biology Services)
  114. BioAge Labs
  115. Bioanalytical Laboratory Services (BLS)
  116. BioAscent
  117. BioBlocks
  118. Bioclinica
  119. BioDuro
  120. Biogen
  121. Biognos
  122. BIOMAPAS CODE OF ETHICS
  123. Biomere
  124. Bioneeds
  125. Bionicsgene
  126. BioNTech
  127. BioPharma Services
  128. BioPredict
  129. Biorasi Clinical Research
  130. BioReliance
  131. bioskin
  132. BioSolveIT
  133. Biospective
  134. BioStat International
  135. BioTek Instruments (part of Agilent Technologies)
  136. Biotoxtech
  137. Biotrial
  138. Biotrofix
  139. Biovantix
  140. BioVectra
  141. BlueClinical
  142. Blueprint Genetics
  143. BOC Sciences
  144. Boston MedTech Advisors
  145. BPI Service (subsidiary of Federal Association of the Pharmaceutical Industry)
  146. BRI Biopharmaceutical Research
  147. BTS Research
  148. Buffalo Institute for Genomics and Data Analytics (BIG)
  149. C&R Research
  150. C.RIS Pharma
  151. Calmark 
  152. Cambrex Zenara (formerly known as Zenara Pharma)
  153. Cambridge Regulatory Services
  154. Carna Biosciences
  155. Cascade Chemistry
  156. Casma Therapeutics
  157. Catalent Pharma
  158. Catalyst Clinical Services
  159. CATO SMS
  160. CCDRD 
  161. CCS Associates (CCSA)
  162. CD BioSciences
  163. Cedilla Therapeutics
  164. Celerion
  165. Center for Pharmacology and Analysis (CEPHA)
  166. Cerbios-Pharma
  167. Certara
  168. Certus International
  169. Charles River Laboratories
  170. CHDI Foundation
  171. Checkpoint Therapeutics 
  172. ChemAxon
  173. ChemBio Discovery Solutions
  174. ChemBridge
  175. ChemDiv
  176. ChemModeling
  177. ChemoGenics BioPharma
  178. Chemotargets
  179. ChemPartner
  180. Chongqing Huapont Pharmaceutical
  181. CIRION
  182. Cliantha Research
  183. ClinAudits
  184. ClinBAY
  185. ClinChoice
  186. ClinDatrix
  187. Clinfinity
  188. Clinical Research Consulting
  189. Clinical Service Center (CSC)
  190. Clinical Trial Service (CTS)
  191. ClinicalConnection
  192. Clinilabs
  193. Clinipace
  194. CliniRx
  195. CLINTRIA
  196. Clinitude
  197. Clinlogix
  198. ClinMax
  199. Clinres Farmacija
  200. ClinServ
  201. ClinSmart
  202. ClinSoft
  203. Clinstat Consulting
  204. Clintec
  205. CluePoints
  206. CMIC Holdings
  207. CNS Contract Research
  208. CNS Pharmaceuticals
  209. Cohortias
  210. Colorado Computational
  211. Comac Medical
  212. ComInnex
  213. Commonwealth Biotechnologies
  214. Comparative Biosciences
  215. Concentrics Research
  216. Concept Life Sciences
  217. Confluence Discovery Technologies
  218. Confo Therapeutics
  219. Congenix
  220. Conifer Point Consulting
  221. Contract Pharmaceuticals
  222. Convex CRO
  223. CordenPharma
  224. CordenPharma
  225. CoreRx
  226. Corlexia Clinical Services
  227. CORONIS Research
  228. Covance
  229. CreaGen
  230. Creative Biostructure
  231. Credevo
  232. Crelux
  233. Cresset
  234. Criterium
  235. CRM-CRO
  236. Crocus Medical
  237. Cromos Pharma
  238. CROPRIME
  239. Crown CRO
  240. CTI
  241. CW Research & Management
  242. CytoAgents
  243. Cytovation
  244. Dabur Research Foundation (DRF)
  245. Dalriada Drug Discovery
  246. Dalton Pharma Services
  247. Datapharm 
  248. DaVinci Biomedical Research Products
  249. DaVita Clinical Research
  250. Deshpande Laboratories
  251. dicentra
  252. Dimension Research
  253. Direct Biologics
  254. DIVERCHIM
  255. Divi's Laboratories
  256. Dizal Pharmaceutical
  257. dMed Biopharmaceutical
  258. DMPK4Biotech
  259. Domainex
  260. Dorian Therapeutics
  261. Double Bond Pharmaceutical
  262. DP Clinical
  263. DPT Laboratories
  264. Drik
  265. DRK Pharma Solutions
  266. DSK InnoSciences
  267. DSP Clinical Research
  268. DyNAbind
  269. DZS Clinical Services
  270. EDASA Scientific
  271. Edelris
  272. EGCP
  273. EGeen
  274. Emerson
  275. Emery Pharma
  276. EMINent Services 
  277. Emissary International
  278. Enamine
  279. Epirium Bio
  280. Equinox Pharma
  281. Ergomed
  282. ERT
  283. ESTERN Medical CRO 
  284. ethica CRO
  285. Eurofins Discovery
  286. Everest Clinical Research
  287. Evonik
  288. Evotec
  289. ExCellThera
  290. Excelya
  291. Experimentica
  292. Explora BioLabs
  293. Farmigea
  294. Farzan Clinical Research
  295. FGK Clinical Research
  296. First Clinical Research
  297. Flamma
  298. Forma Therapeutics
  299. Frontage Laboratories
  300. Galapagos 
  301. Gavi
  302. GB Pharma
  303. Gedeon Richter
  304. Gencore BioPharma
  305. Genentech
  306. Genesis Drug Discovery & Development
  307. Genetron Holdings
  308. Genpro Research
  309. George Clinical
  310. GI Innovation
  311. GI Reviewers
  312. Gilead Sciences
  313. Global Center for Medical Innovation (GCMI)
  314. GMP Bio
  315. Gotham Therapeutics
  316. GP Pharm
  317. Grayline Research Center
  318. Green Cross Lab Cell
  319. GRK Research Laboratories
  320. GVK Biosciences
  321. H&J CRO International
  322. Hamamatsu Pharma Research (HPR)
  323. Harvis Pharm
  324. Health Decisions
  325. HealthCare Global Enterprises
  326. Highlight Therapeutics
  327. Hikma Pharmaceuticals
  328. Hippocrates Research (HR)
  329. HitGen
  330. Holburn Biomedical
  331. Hoth Therapeutics
  332. HungaroTrial
  333. Hurley Consulting Associates
  334. Hyperion Biotechnology
  335. ICON
  336. International Drug Development Institute (IDDI)
  337. IIT Delhi
  338. IKCON PHARMA
  339. Immunocure Discovery Solutions
  340. Imperial Clinical Research Services
  341. Imperial College London
  342. ImQuest BioSciences
  343. InCROM
  344. Indivirtus
  345. Info Kinetics
  346. InformedDNA
  347. IniXium
  348. Innovative Informatica Technologies
  349. Inotiv
  350. Inoviem
  351. Inspire
  352. Integral Biosciences
  353. Integrium
  354. InteRNA Technologies
  355. International Clinical Trials Association
  356. International HealthCare (IHC) 
  357. Intonation Research Laboratories
  358. Intrials Clinical Research
  359. Invivoscribe 
  360. IonsGate Preclincal Services 
  361. IPS Therapeutique (IPST)
  362. IQVIA
  363. IRBM
  364. Iris Pharma
  365. IRW
  366. Isochem
  367. JANIX
  368. Janssen Biotech
  369. Jehangir Clinical Development Centre (JCDC)
  370. JOANNEUM RESEARCH
  371. JRF Global
  372. JSS Medical Research
  373. Jubilant Biosys
  374. Julius Clinical
  375. Kalexsyn
  376. KCAS Bioanalytical and Biomarker Services
  377. KCR
  378. Key Organics
  379. Klinar
  380. KMR Group
  381. KP Pharmaceutical Technology
  382. KPS Clinical Services
  383. Kriger Research International
  384. Kymera
  385. Lambda Therapeutics Research 
  386. Lancaster University
  387. Laurus Synthesis
  388. LAVA Therapeutics
  389. LAXAI Life Sciences (a subsidiary of Laxai Pharma)
  390. LegoChem Biosciences (LCB)
  391. Leon Research
  392. LG Chem
  393. Liatris Biosciences
  394. Life Chemicals
  395. Linical
  396. LINK Medical
  397. Lipigon
  398. Liverpool ChiroChem
  399. Lonza
  400. Lotus Clinical Research
  401. Lotus Pharmaceuticals
  402. LSK Global Pharma Services
  403. Lubrizol Life Science (LLS Health)
  404. Lucid Diagnostics
  405. MakroCare
  406. Marksman Healthcare
  407. Mascot Industries
  408. MB Quest
  409. Medelis
  410. Medfiles
  411. Medi Service
  412. Medical Data Analytics (MDA)
  413. Medicilon
  414. Medicines Evaluation Unit (MEU) 
  415. Medidata Solutions
  416. Mediolanum Cardio Research (MCR)
  417. Mediprobe Research
  418. Medis Research Group
  419. Medpace
  420. MedPharm
  421. MedReleaf
  422. MedTrials
  423. MENADIONA
  424. MENE Health Group (MHG)
  425. Merck & Co.
  426. Meruvax Pharma
  427. Metrics Champion Consortium (MCC)
  428. Metrics Contract Services
  429. Metrics Research
  430. Micar Innovation
  431. Micro Therapeutic Research Labs (MTRL)
  432. MicroConstants
  433. Micro-Sphere
  434. Mitsubishi Tanabe Pharma
  435. MLM Medical Labs
  436. MMS Holdings
  437. Molcan
  438. Molecular Cornerstones
  439. Molecular Forecaster
  440. Molecule CRO
  441. Molsoft
  442. Moncoa Medical Research
  443. Monipol
  444. Monitioring Force
  445. MonitorCRO
  446. Morley Research Consortium
  447. Morphic
  448. MRI Global
  449. MSN Laboratories
  450. MTZ Clinical Research
  451. My Green Lab
  452. Nagy Research
  453. Nanjing Pharmatechs
  454. Nanosyn
  455. Nanyang Technological University (NTU)
  456. National Cancer Institute
  457. NCGS
  458. Neurofit
  459. Neurosolutions
  460. New England Discovery Partners (NEDP)
  461. Next Pharma
  462. Nextar Chempharma Solutions
  463. NexusPharma
  464. NIAID
  465. Nitza Bioventure
  466. NMX Research and Solutions
  467. Noble Life Sciences
  468. NorthEast BioLab
  469. NorthWise Services
  470. Norwich Clinical Research Associates
  471. Nostrum Biodiscovery
  472. NovaData Solutions
  473. NovAlix
  474. NovaMechanics
  475. Novotech
  476. NTZ Lab
  477. NuChem Therapeutics
  478. Nutrasource
  479. Nuvisan Pharma
  480. OCT Clinical
  481. OMass Therapeutics
  482. Oncodesign
  483. Oncology Ventures
  484. ONCOtherapeutics
  485. Onq Research
  486. OpenEye Scientific
  487. Open Orphan
  488. Operatrix Consulting
  489. OPN Healthcare
  490. Ora Clinical
  491. Orbis Clinical
  492. Organo Chem
  493. Oroxcell
  494. Orphan Reach
  495. Osong
  496. OTAVA Chemicals
  497. P3 Research
  498. Pacific BioLabs
  499. Pacific Bridge Medical
  500. Palm Beach CRO
  501. Palobiofarma
  502. Paraxel
  503. Paraza Pharma
  504. Patheon by Thermo Fischer Scientific
  505. Peachtree BioResearch Solutions
  506. PELVIPHARM
  507. ProXyChem
  508. Pfizer CentreOne®
  509. Pharma Inventor
  510. Pharma Medica Research
  511. Pharmacelera
  512. Pharmaceuticals Product Development
  513. Pharmaffiliates
  514. Pharmahungary
  515. PharmAI
  516. Pharmalys
  517. PharmaResources
  518. Pharmaron
  519. PharmaSeek (acquired by WCG)
  520. Pharmatest Services
  521. Pharm-Olam
  522. PharmStats
  523. PharSafer®
  524. PHASTAR
  525. PHDS Healthcare Research
  526. Phoneix Clinical Research
  527. Physiogenex
  528. Pierrel SpA
  529. pilot Mainz 
  530. Pion
  531. Piramal Pharma Solutions
  532. Pivotal
  533. POPSI CUBE
  534. Porton Fine Chemicals
  535. PPC Group
  536. PRA Health Sciences
  537. Premier Research
  538. Prestwick Chemical
  539. Princeton BioMolecular Research
  540. Procaps
  541. ProDERM
  542. Profacgen
  543. Profil
  544. Proinnovera
  545. Promedica International
  546. PROMETRIKA
  547. ProRelix Research
  548. Prosarix 
  549. Proswell Medical
  550. Proteros Fragments
  551. ProtoQSAR
  552. Provid Pharmaceuticals
  553. Providence Clinical Research
  554. Proxima
  555. Proximagen
  556. ProXyChem
  557. ProZyme
  558. Prudentia Group
  559. PSI
  560. Pyramid Laboratories
  561. Pyxis Discovery
  562. QPS
  563. Q-Trials
  564. Quality Assistance
  565. Quality Chemical Laboratories
  566. Quanticate
  567. Quartesian
  568. Quay Pharmaceuticals
  569. Quotient Sciences
  570. Raptim Research
  571. RASA Lifescience Informatics
  572. Raybow Pharmaceuticals
  573. Reaction Biology
  574. Reaxense
  575. Recipharm
  576. Red Glead Discovery
  577. Redox Scientific
  578. Redoxis
  579. Reliance Life Sciences
  580. Research Assist
  581. Resolution Bioscience
  582. Resolution Latin America
  583. Rho
  584. Richmond Pharmacology 
  585. Rottendorf Pharma
  586. RTI Health Solutions
  587. RTI International
  588. Sacura
  589. Sai Life Sciences
  590. Sambi Pharma
  591. Sandexis Molecular Design
  592. Sanjeevani Bio
  593. Sanofi
  594. Sarah Cannon Development Innovations
  595. SARomics Biostructures
  596. Scandinavian CRO
  597. Schiff & Company
  598. SchinoPharm
  599. Scian services
  600. Scientific Bio-minds
  601. Scimega
  602. SchinoPharm
  603. Scope International
  604. Sekisui Xenotech
  605. Selvita
  606. SGS Life Sciences
  607. SGS Life Sciences
  608. Shamrock Structures
  609. Siegfried
  610. SilcsBio
  611. SILLAR CLINICAL 
  612. Simbec-Orion
  613. Simulations Plus
  614. Sinclair Research
  615. Sipra Labs
  616. SiREEN
  617. Sitryx Therapeutics
  618. SLG
  619. SLR Biosciences
  620. Smerud Medical Research Group
  621. Smerud Medical Research International
  622. SMO India
  623. SNBL Japan
  624. SoBran Bioscience
  625. SOCAR Research
  626. SofPromed
  627. Solvias
  628. SomaLogic
  629. Sovereign Pharmaceuticals
  630. Spaulding Clinical
  631. Spectrum Clinical Research
  632. Sphaera Pharma
  633. SpiroChem
  634. SPRI Ukraine
  635. Squarepoint-Pointcare
  636. Staidson
  637. Standard Medical Products
  638. Statistics Collaborative
  639. STATKING Clinical Services
  640. Stiris Research
  641. Strain Chem
  642. Strand Life Sciences
  643. Strategic Regulatory Consulting
  644. Structure Based Design
  645. Sugen Life Sciences
  646. Sun Pharma Advanced Research Company
  647. Sundia
  648. Sundia MediTech
  649. SuperLab
  650. Swiss Pharma
  651. Sygnature Discovery
  652. Symbio Research
  653. Symeres
  654. Symphony Pharma Life Science
  655. Synapse
  656. Synchron 
  657. Syneos Health
  658. Synergy Research Group
  659. Syngene
  660. SynphaTec Japon
  661. SYNSIGHT
  662. Synteract
  663. SYNthesis med chem
  664. Syreon Clinical Research
  665. Sysdata Consulting
  666. T3D Therapeutics
  667. Takeda Pharmaceutical
  668. Target Health
  669. Taros Chemicals
  670. TCA Clinical Research
  671. TCG Lifesciences
  672. Tech Observer
  673. TFS HealthScience
  674. The Alliance for Clinical Trials in Oncology
  675. The Avoca Group
  676. The Kitasato Institute
  677. The Micron Group
  678. The Siesta Group
  679. The SIRO Clinpharm
  680. Theradex Oncology
  681. TheraIndx Lifesciences
  682. Therapeutics
  683. Tigermed
  684. TimTec
  685. Titan Pharma
  686. TKL Research
  687. TMG Research
  688. Tolmar
  689. Tonus-Les
  690. Torrent Pharm
  691. Toxikon 
  692. TransPharm Preclinical Solutions
  693. Trennic Data Services
  694. Trifecta Clinical
  695. Tubilux Pharma (acquired by C.O.C Farmaceutici)
  696. ULTRA Scientific
  697. Ultratech India
  698. Unichem Laboratories
  699. Unimark Remedies
  700. Unison
  701. University of Edinburgh
  702. University of Manchester
  703. University of Sheffield 
  704. UPM Pharmaceuticals
  705. UPPTHERA
  706. US Pharma Lab
  707. USV
  708. Vagdevi InnoScience
  709. Veeda CRO
  710. Velesco Pharmaceutical Services
  711. Velos
  712. Vergo Pharma Research
  713. Veristat
  714. Vernalis
  715. Verum Clinical Research
  716. Vimta Labs
  717. Vipergen
  718. Vipragen Biosciences
  719. Viva Biotech
  720. Vlife Sciences
  721. Vyome Therapeutics
  722. Waife & Associates
  723. WellSpring Consumer Healthcare
  724. Westat 
  725. Wilmington PharmaTech
  726. Windlas
  727. Windlas Healthcare
  728. Winicker Norimed
  729. WCG IRB 
  730. Wisdom Pharmaceuticals
  731. Worldwide Clinical Trials
  732. WuXi AppTec
  733. XoNovo
  734. Xpose Therapeutics
  735. Xtal BioStructures
  736. Yaadvi Scientific Solutions
  737. Yale University
  738. Yao Pharma
  739. Young In Scientific
  740. Yung Zip Chemical
  741. Zaggo
  742. Zambon
  743. ZEINCRO
  744. Zenith Healthcare
  745. Zenobia Fragments
  746. ZenRise
  747. Apeloa Pharma
  748. Zhejiang Langhua Pharmaceutical
  749. ZM Company
  750. ZoBio
  751. Zydus BSV Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com